BOSTON, Mass. and GENEVA, Switzerland – PHT Corporation announced the selection of the Hewlett Packard (HP) ElitePad 1000 G2 with Windows 8.1 for its SitePad® System. The SitePad System replaces paper data collection methods in clinical trials that collect clinician- and patient-reported outcomes for supporting label claims of new drugs. PHT is the leading provider of mobile apps used to collect patient-driven eData for clinical research.
The SitePad System is used to collect clinician-driven endpoints such as disease progression, impression and assessments as well as patient reported outcomes and quality of life data directly from patients. The SitePad is configured to the requirements of clinical protocols and the study specific data collected is sent securely to StudyWorks™, the PHT online portal that provides real-time information about study compliance plus key measures used for operations and patient safety monitoring. Protocol compliance with the SitePad System exceeds 98.5% historically over 130 trials.
Demand for the PHT SitePad System has been growing steadily in recent years across therapeutic areas including oncology, immunology, and CNS. Clients are using the SitePad to increase the quality and efficiency of both patient and clinician reported outcomes across indications and do not want paper to be a rate limiting step in the clinical trial process. The SitePad System delivers higher quality data and faster time to data analysis for clinical trial sponsors. Watch a brief video: http://bit.ly/1cpCXcl
Sheila Rocchio, PHT Vice President of Marketing and Corporate Strategy, commented, “Sponsors and CROs rely on the SitePad System for trials of all types because it offers a reliable, easy-to-use and regulatory compliant method for increasing data quality and protocol compliance. The SitePad System supports risked based monitoring strategies by providing real-time access to endpoint data and has been proven to significantly reduce monitoring and data management costs. In a recent Phase III trial, using the SitePad was 30% more cost effective than using paper.”
The HP ElitePad 1000 G2 contains an Intel® 64-bit Atom processor. It weighs 1.5 lbs and is one of the thinnest tablets in the industry, at 9.2 mm. Features include wider viewing angles on the outdoor-viewable 10.1-inch diagonal WUXGA multi-touch panel; wireless connection, including optional worldwide 4G LTE with HP Connection Manager; and, support for touch, pen or voice-based input. The HP ElitePad 1000 G2 offers enhanced protection against virus attack, with a design that helps prevent data loss and reduce downtime.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.